Cut­ting back in the UK, Take­da spins out its top neu­ro­science team in­to a transat­lantic biotech

As Take­da con­tin­ues a glob­al R&D over­haul that in­cludes a wind down of UK op­er­a­tions, the Japan­ese phar­ma com­pa­ny is spin­ning out its neu­ro­science team in­to a new biotech called Cere­vance, which will have roots in the two Cam­bridges on both sides of the At­lantic.

Mark Carl­ton, the for­mer pres­i­dent and CSO of Take­da Cam­bridge (UK), and his 25-mem­ber team — com­plete with a well equipped lab — have be­come the core group be­hind Cere­vance. The new biotech is get­ting start­ed with $36 mil­lion in fund­ing, in­clud­ing $21.5 mil­lion from Take­da and Light­stone Ven­tures. And it will jump in­to ex­is­tence with a port­fo­lio of pre­clin­i­cal and clin­i­cal pro­grams un­der­way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER